PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) is curative but is associated with life-threatening complications. Most deaths occur within the first 2 years after transplantation. In this report, we examine long-term survival in 2-year survivors in the largest cohort ever studied. PATIENTS AND METHODS: Records of 10,632 patients worldwide reported to the Center for International Blood and Marrow Transplant Research who were alive and disease free 2 years after receiving a myeloablative allogeneic HCT before 2004 for acute myelogenous or lymphoblastic leukemia, myelodysplastic syndrome, lymphoma, or severe aplastic anemia were reviewed. RESULTS: Median follow-up was 9 years, and 3,788 patients had been observed for 10 or more years. The probability of being alive 10 years after HCT was 85%. The chief risk factors for late death included older age and chronic graft-versus-host disease (GVHD). For patients who underwent transplantation for malignancy, relapse was the most common cause of death. The greatest risk factor for late relapse was advanced disease at transplantation. Principal risk factors for nonrelapse deaths were older age and GVHD. When compared with age, sex, and nationality-matched general population, late deaths remained higher than expected for each disease, with the possible exception of lymphoma, although the relative risk generally receded over time. CONCLUSION: The prospect for long-term survival is excellent for 2-year survivors of allogeneic HCT. However, life expectancy remains lower than expected. Performance of HCT earlier in the course of disease, control of GVHD, enhancement of immune reconstitution, less toxic regimens, and prevention and early treatment of late complications are needed.
PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) is curative but is associated with life-threatening complications. Most deaths occur within the first 2 years after transplantation. In this report, we examine long-term survival in 2-year survivors in the largest cohort ever studied. PATIENTS AND METHODS: Records of 10,632 patients worldwide reported to the Center for International Blood and Marrow Transplant Research who were alive and disease free 2 years after receiving a myeloablative allogeneic HCT before 2004 for acute myelogenous or lymphoblastic leukemia, myelodysplastic syndrome, lymphoma, or severe aplastic anemia were reviewed. RESULTS: Median follow-up was 9 years, and 3,788 patients had been observed for 10 or more years. The probability of being alive 10 years after HCT was 85%. The chief risk factors for late death included older age and chronic graft-versus-host disease (GVHD). For patients who underwent transplantation for malignancy, relapse was the most common cause of death. The greatest risk factor for late relapse was advanced disease at transplantation. Principal risk factors for nonrelapse deaths were older age and GVHD. When compared with age, sex, and nationality-matched general population, late deaths remained higher than expected for each disease, with the possible exception of lymphoma, although the relative risk generally receded over time. CONCLUSION: The prospect for long-term survival is excellent for 2-year survivors of allogeneic HCT. However, life expectancy remains lower than expected. Performance of HCT earlier in the course of disease, control of GVHD, enhancement of immune reconstitution, less toxic regimens, and prevention and early treatment of late complications are needed.
Authors: A Krishnan; S Bhatia; M L Slovak; D A Arber; J C Niland; A Nademanee; H Fung; R Bhatia; A Kashyap; A Molina; M R O'Donnell; P A Parker; I Sniecinski; D S Snyder; R Spielberger; A Stein; S J Forman Journal: Blood Date: 2000-03-01 Impact factor: 22.113
Authors: S Bhatia; A D Louie; R Bhatia; M R O'Donnell; H Fung; A Kashyap; A Krishnan; A Molina; A Nademanee; J C Niland; P A Parker; D S Snyder; R Spielberger; A Stein; S J Forman Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: John M Goldman; Navneet S Majhail; John P Klein; Zhiwei Wang; Kathleen A Sobocinski; Mukta Arora; Mary M Horowitz; J Douglas Rizzo Journal: J Clin Oncol Date: 2010-03-08 Impact factor: 44.544
Authors: N S Majhail; R Bajorunaite; H M Lazarus; Z Wang; J P Klein; M J Zhang; J D Rizzo Journal: Bone Marrow Transplant Date: 2010-05-17 Impact factor: 5.483
Authors: Catherine Metayer; Rochelle E Curtis; Julie Vose; Kathleen A Sobocinski; Mary M Horowitz; Smita Bhatia; Joseph W Fay; Cesar O Freytes; Steven C Goldstein; Roger H Herzig; Armand Keating; Carol B Miller; Thomas J Nevill; Andrew L Pecora; J Douglas Rizzo; Stephanie F Williams; Chin-Yang Li; Lois B Travis; Daniel J Weisdorf Journal: Blood Date: 2002-10-10 Impact factor: 22.113
Authors: Nandita Khera; Barry Storer; Mary E D Flowers; Paul A Carpenter; Yoshihiro Inamoto; Brenda M Sandmaier; Paul J Martin; Stephanie J Lee Journal: J Clin Oncol Date: 2011-12-05 Impact factor: 44.544
Authors: Saro H Armenian; Dongyun Yang; Jennifer Berano Teh; Liezl C Atencio; Alicia Gonzales; F Lennie Wong; Wendy M Leisenring; Stephen J Forman; Ryotaro Nakamura; Eric J Chow Journal: Blood Adv Date: 2018-07-24
Authors: Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard Journal: Biol Blood Marrow Transplant Date: 2016-10-14 Impact factor: 5.742
Authors: Yusuke Shono; Andrea Z Tuckett; Samedy Ouk; Hsiou-Chi Liou; Grégoire Altan-Bonnet; Jennifer J Tsai; Jennifer E Oyler; Odette M Smith; Mallory L West; Natalie V Singer; Ekaterina Doubrovina; Dmitry Pankov; Chandresh V Undhad; George F Murphy; Cecilia Lezcano; Chen Liu; Richard J O'Reilly; Marcel R M van den Brink; Johannes L Zakrzewski Journal: Cancer Discov Date: 2014-02-18 Impact factor: 39.397
Authors: Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann Journal: Lancet Haematol Date: 2018-06-18 Impact factor: 18.959